Nizatidine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Cyberfan195 (talk | contribs) at 22:49, 1 February 2020 (→‎External links: adding it to Eli Lilly and Company brands.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Nizatidine
Clinical data
Trade namesAxid, Tazac
AHFS/Drugs.comMonograph
MedlinePlusa694030
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability>70%
Protein binding35%
MetabolismLiver
Elimination half-life1–2 hours
ExcretionKidney
Identifiers
  • (E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.155.683 Edit this at Wikidata
Chemical and physical data
FormulaC12H21N5O2S2
Molar mass331.46 g/mol g·mol−1
3D model (JSmol)
  • [O-][N+](=O)\C=C(/NC)NCCSCc1nc(sc1)CN(C)C
  • InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+ checkY
  • Key:SGXXNSQHWDMGGP-IZZDOVSWSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

It was patented in 1980 and approved for medical use in 1987.[2] It was developed by Eli Lilly. Brand names include Tazac and Axid.

Medical use

Main article: H2 antagonist

Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD/GORD), and to prevent stress ulcers.[1]

Adverse effects

Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.[1]

History and development

Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.[3] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).[4] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent[5] protecting the product) to Braintree Laboratories.[6]

Nizatidine proved to be the last new histamine H2 receptor antagonist introduced prior to the advent of proton pump inhibitors.[citation needed]

See also

  • Famotidine (Pepcid) — another popular H2 receptor antagonist

References

  1. ^ a b c "Nizatidine". Livertox.nih.gov. Retrieved 2015-10-11.
  2. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 44. ISBN 9783527607495.
  3. ^ [1] Archived May 26, 2008, at the Wayback Machine
  4. ^ [2] Archived December 26, 2013, at the Wayback Machine
  5. ^ "United States Patent: 6930119". Patft.uspto.gov. Retrieved 2015-10-11.
  6. ^ [3] Archived August 14, 2007, at the Wayback Machine

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Nizatidine&oldid=938712669"